Noriaki Numata

Noriaki Numata

Auto-generated profile, based on publicly available information

Noriaki Numata

Technical Center, Jellice Co., Ltd., 4-4-1 Sakae, Tagajo, Miyagi 985-0833, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Behavioural Brain Research
Verified
Journal Article
Closed access
HKHidekazu Kaneko
Hidekazu Kaneko
MNMasakazu Namihira
Masakazu Namihira
SYShoko Yamamoto
Shoko Yamamoto
NNNoriaki Numata
Noriaki Numata
KHKoji Hyodo
Koji Hyodo

1 February 2026 in Protein & Peptide Letters
Verified
Journal Article
Closed access
PDF file
SYShoko Yamamoto
Shoko Yamamoto
YMYo Matsumoto
Yo Matsumoto
FYFumihiro Yanbe
Fumihiro Yanbe
ASAkiko Sakai-Sakasai
Akiko Sakai-Sakasai
MTMasayoshi Takeuchi
Masayoshi Takeuchi
NNNoriaki Numata
Noriaki Numata
Introduction: Long-term intake of Collagen Tripeptide (CTP), which is rich in Glycine- X-Y sequences, improves blood vessel elasticity and reduces the serum levels of cytotoxic glyceraldehyde (GA)-derived Advanced Glycation End-Products (AGEs), also known as Toxic AGEs (TAGE). Therefore, the anti-glycation effect of CTP may be one of the mechanisms contributing to its ability to improve vascular elasticity. This study aims to investigate the antiglycation effects of the tripeptide, glycine-proline-hydroxyproline (Gly-Pro-Hyp; GPHyp), the main component of CTP, using in vitro GA glycation models and comparing its metabolite sequences. Methods: Cell viability and mRNA expression were measured in GA-treated HepG2 cells with or without the addition of GPHyp. The half-maximal inhibitory concentration (IC50) of GPHyp for inhibiting TAGE formation and for inhibiting lysozyme glycation crosslinking was evaluated. Results: Only GPHyp significantly suppressed cell death and interleukin-8 (IL-8) mRNA expression in GA-treated cells. The IC50 for TAGE production and inhibitory effect on lysozyme crosslinking demonstrated that GPHyp exhibited stronger anti-glycation effects than its metabolite amino acids and peptides. The addition of GPHyp also resulted in increased GA consumption. Analysis of the changes in GA concentrations during the reaction revealed that the addition of GPHyp significantly reduced GA levels within the first hour. Discussion: These results suggest that GPHyp possesses potent GA-scavenging activity and inhibits TAGE production, contributing to the CTP-mediated reduction in serum TAGE levels and to improvements in vascular elasticity. Conclusion: The anti-glycation effect of GPHyp may support a healthy lifestyle and warrant further investigation.

1 February 2013 in Journal of Dermatological Science
Verified
Journal Article
Closed access
TOTomoko Okawa
Tomoko Okawa
YYYukie Yamaguchi
Yukie Yamaguchi
STShinnosuke Takada
Shinnosuke Takada
YSYasuo Sakai
Yasuo Sakai
NNNoriaki Numata
Noriaki Numata
MAMichiko Aihara
Michiko Aihara